Suchergebnisse - "Fajgenbaum, David C."

PubPharm (6)

1

Increased mTOR activation in idiopathic multicentric Castleman disease

enthalten in: Blood | 2020

von Arenas, D. | Floess, K. | Kobrin, D. | +14

CommentIn: Blood. 2020 May 7;135(19):1614-1615. - PMID 32379877

2

Overview of Castleman disease

enthalten in: Blood | 2020

von Dispenzieri, A. | Fajgenbaum, D.

3

Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease

enthalten in: Blood | 2019

von Zhang, L. | Zhao, A. | Duan, M. | +7

CommentIn: Blood. 2019 Apr 18;133(16):1697-1698. - PMID 31000513

4

International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease

enthalten in: Blood | 2017

von Fajgenbaum, D. | Uldrick, T. | Bagg, A. | +35

5

Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease

enthalten in: Blood | 2017

von Yu, L. | Tu, M. | Cortes, J. | +13

CommentIn: Blood. 2017 Mar 23;129(12 ):1570. - PMID 28336728

6

HHV-8-negative, idiopathic multicentric Castleman disease : novel insights into biology, pathogenesis, and therapy

enthalten in: Blood | 2014

von Fajgenbaum, D. | van Rhee, F. | Nabel, C.

1
[1]